drugset / Trial / NCT03467113
A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol
NaSingle-groupOpen-labelTreatment
Summary
This is an open label study to evaluate the safety of ZX008 (fenfluramine) in patients with Dravet syndrome (DS) or Lennox Gastaut syndrome (LGS) who are being administered cannabidiol (CBD).
Timeline
- Start
- 2018-01-19
- Primary completion
- 2020-06-24
- Completion
- 2020-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fenfluramine | Small molecule | 0.2 mg/kg | Oral |
| Subject | Fenfluramine | Small molecule | 0.8 mg/kg | Oral |
| Background | Cannabidiol | Other / unclassified | — | — |